ORASURE TECHNOLOGIES, INC. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(Unaudited)
(in thousands, except per share amounts, unless otherwise indicated)
Our business consists of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our molecular products and services business, or DNAG business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, pharmacogenomics, personalized medicine, microbiome and animal genetics markets. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory and bioinformatics services.
Our OSUR diagnostic products include tests for diseases including HIV and Hepatitis C that are performed on a rapid basis at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, and other public health organizations, distributors, government agencies, physicians’ offices, and commercial and industrial entities. Our HIV product is also sold in a consumer-friendly format in the over-the-counter (“OTC”) market in the U.S. and as a self-test to individuals in a number of other countries. We also previously manufactured and sold medical devices used for the removal of benign skin lesions by cryosurgery or freezing. We sold the assets associated with our cryosurgical systems business to a third party in August 2019. See further discussion at Note 4.
Our DNAG business is operated by our subsidiaries, DNA Genotek Inc. (“DNAG”), CoreBiome Inc. (“CoreBiome”), Novosanis NV (“Novosanis”), and Diversigen, Inc. (“Diversigen”). DNAG’s specimen collection devices provide all-in-one systems for the collection, stabilization, transportation and storage of nucleic acids from human saliva and other sample types for genetic and microbiome applications. CoreBiome and Diversigen provide laboratory and bioinformatics services. Novosanis’ Colli-Pee collection device is designed for the volumetric collection of first-void urine for use in research, screening and diagnostics for the liquid biopsy and sexually transmitted infection markets. We also sell research use only sample collection products into the microbiome market and we offer our customers a suite of genomics and microbiome services, which range from package customization and study design optimization to extraction, analysis and reporting services. We serve customers worldwide in the research, healthcare, pharmaceutical and agricultural communities.
2.
|
Summary of Significant Accounting Policies
|
Principles of Consolidation and Basis of Presentation. The consolidated financial statements include the accounts of OraSure Technologies, Inc. (“OraSure”) and its wholly-owned subsidiaries, DNAG, CoreBiome, Novosanis and Diversigen. All intercompany transactions and balances have been eliminated. References herein to “we,” “us,” “our,” or the “Company” mean OraSure and its consolidated subsidiaries, unless otherwise indicated.
The accompanying consolidated financial statements are unaudited and, in the opinion of management, include all adjustments (consisting only of normal and recurring adjustments) necessary for a fair presentation of our financial position and results of operations for these interim periods. These financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Results of operations for the three months ended March 31, 2020 are not necessarily indicative of the results of operations expected for the full year.
Use of Estimates. The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions about future events. These estimates and underlying assumptions affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Such estimates include the fair value of assets acquired and liabilities assumed for business combinations, the valuation of accounts receivable and inventories and assumptions utilized in impairment testing for intangible assets and goodwill, as well as calculations related to accruals, taxes, contingent consideration, and performance-based compensation expense, among others. These estimates and assumptions are based on management’s best estimates and judgment. Management evaluates its estimates and assumptions on an ongoing basis, using historical experience and other factors, which management believes to be reasonable under the circumstances, including the current economic environment. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in those estimates resulting from continuing changes in the economic environment and other factors will be reflected in the financial statements in those future periods.
Investments. We consider all investments in debt securities to be available-for-sale securities. These securities consist of guaranteed investment certificates and corporate bonds with purchased maturities greater than ninety days. Available-for-sale securities are carried at fair value, based upon quoted market prices, with unrealized gains and losses, if any, reported in stockholders’ equity as a component of accumulated other comprehensive loss.
-7-
We record an allowance for credit loss for our available-for-sale securities when a decline in investment market value is due to credit-related factors. When evaluating an investment for impairment, we review factors such as the severity of the impairment, changes in underlying credit ratings, forecasted recovery, the Company’s intent to sell or the likelihood that it would be required to sell the investment before its anticipated recovery in market value and the probability that the scheduled cash payments will continue to be made. As of March 31, 2020, we determined that the decline in the market value of our available-for-sale investment was not due to credit-related factors and as such no allowance for credit-loss was necessary.
The following is a summary of our available-for-sale securities as of March 31, 2020 and December 31, 2019:
|
|
Amortized
Cost
|
|
|
Gross
Unrealized
Gains
|
|
|
Gross
Unrealized
Losses
|
|
|
Fair Value
|
|
March 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Guaranteed investment certificates
|
|
$
|
22,757
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
22,757
|
|
Corporate bonds
|
|
|
70,604
|
|
|
|
94
|
|
|
|
(650
|
)
|
|
|
70,048
|
|
Total available-for-sale securities
|
|
$
|
93,361
|
|
|
$
|
94
|
|
|
$
|
(650
|
)
|
|
$
|
92,805
|
|
December 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Guaranteed investment certificates
|
|
$
|
24,632
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
24,632
|
|
Corporate bonds
|
|
|
89,525
|
|
|
|
271
|
|
|
|
(385
|
)
|
|
|
89,411
|
|
Total available-for-sale securities
|
|
$
|
114,157
|
|
|
$
|
271
|
|
|
$
|
(385
|
)
|
|
$
|
114,043
|
|
At March 31, 2020, maturities of our available-for-sale
securities were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less than one year
|
|
$
|
83,274
|
|
|
$
|
94
|
|
|
$
|
(633
|
)
|
|
$
|
82,735
|
|
Greater than one year
|
|
$
|
10,087
|
|
|
$
|
—
|
|
|
$
|
(17
|
)
|
|
$
|
10,070
|
|
Fair Value of Financial Instruments. As of March 31, 2020 and December 31, 2019, the carrying values of cash and cash equivalents, accounts receivable, and accounts payable approximate their respective fair values based on their short-term nature.
Fair value measurements of all financial assets and liabilities that are being measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
All of our available-for-sale securities are measured as Level 2 instruments as of March 31, 2020 and December 31, 2019.
Included in cash and cash equivalents at March 31, 2020 and December 31, 2019, was $21,660 and $1,624 invested in government money market funds. These funds have investments in government securities and are measured as Level 1 instruments.
We offer a nonqualified deferred compensation plan for certain eligible employees and members of our Board of Directors. The assets of the plan are held in the name of the Company at a third-party financial institution. Separate accounts are maintained for each participant to reflect the amounts deferred by the participant and all earnings and losses on those deferred amounts. The assets of the plan are held in mutual funds. The fair value of the plan assets as of March 31, 2020 and December 31, 2019 was $3,444 and $3,519, respectively, and was calculated using the quoted market prices of the assets as of those dates. All investments in the plan are classified as trading securities and measured as Level 1 instruments. The fair value of plan assets is included in both current assets and noncurrent assets with the same amount included in accrued expenses and other noncurrent liabilities in the accompanying consolidated balance sheets.
-8-
Accounts Receivable. Accounts receivable have been reduced by an estimated allowance for amounts that may become uncollectible in the future. This estimated allowance is based primarily on management’s evaluation of specific balances as they become past due, the financial condition of our customers and our historical experience related to write-offs.
Inventories. Inventories are stated at the lower of cost or net realizable value with cost determined on a first-in, first-out basis, and consist of the following:
|
|
March 31,
2020
|
|
|
December 31,
2019
|
|
Raw materials
|
|
$
|
13,927
|
|
|
$
|
14,168
|
|
Work in process
|
|
|
865
|
|
|
|
643
|
|
Finished goods
|
|
|
7,902
|
|
|
|
8,344
|
|
|
|
$
|
22,694
|
|
|
$
|
23,155
|
|
Property, Plant and Equipment. Property, plant and equipment are stated at cost. Additions or improvements are capitalized, while repairs and maintenance are charged to expense. Depreciation and amortization are provided using the straight-line method over the estimated useful lives of the related assets. Buildings are depreciated over twenty to forty years, while computer equipment, machinery and equipment, and furniture and fixtures are depreciated over two to ten years. Building improvements are amortized over their estimated useful lives. When assets are sold, retired, or discarded, the related property amounts are relieved from the accounts, and any gain or loss is recorded in the consolidated statements of operations. Accumulated depreciation of property, plant and equipment as of March 31, 2020 and December 31, 2019 was $49,417 and $46,882, respectively.
Intangible Assets. Intangible assets consist of customer relationships, patents and product rights, acquired technology and tradenames. Patents and product rights consist of costs associated with the acquisition of patents, licenses, and product distribution rights. Intangible assets are amortized using the straight-line method over their estimated useful lives of five to fifteen years. Accumulated amortization of intangible assets as of March 31, 2020 and December 31, 2019 was $22,812 and $23,420, respectively. The change in intangibles from $14,674 as of December 31, 2019 to $15,746 as of March 31, 2020 is a result of the acquisition of patent and product rights of $2,250 offset by foreign currency translation losses of $446 and $732 in amortization expense.
Goodwill. Goodwill represents the excess of the purchase price we paid over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in our acquisitions of DNAG, CoreBiome, Novosanis and Diversigen. All acquired goodwill has been allocated to our DNAG segment. Goodwill is not amortized but rather is tested annually for impairment or more frequently if we believe that indicators of impairment exist. Current U.S. generally accepted accounting principles permit us to make a qualitative evaluation about the likelihood of goodwill impairment. If we conclude that it is more likely than not that the carrying value of a reporting unit is greater than its fair value, then we would be required to recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.
The decrease in goodwill from $36,201 as of December 31, 2019 to $34,544 as of March 31, 2020 is a result of a purchase price adjustment related to one of our acquisitions of $126 and a decrease of $1,531 associated with foreign currency translation.
Leases. In February 2019, the FASB issued ASU No. 2016-02, Leases. The standard requires lessees to recognize lease assets and lease liabilities on the balance sheet and requires expanded disclosures about leasing arrangements. We adopted this standard on January 1, 2019 on a modified retrospective basis and did not restate comparative amounts. Also, we elected the practical expedients permitted under the transition guidance, which allows us to carryforward our historical lease classification, our assessment on whether a contract is or contains a lease, and our initial direct costs for any leases that exist prior to adoption of the new standard. Leases with an initial term of 12 months or less are not recognized on the balance sheet and the associated lease payments are included in the consolidated statements of operations on a straight-line basis over the lease term. As a result, on January 1, 2019, we recorded right-of-use assets of $4,027 and lease liabilities of $4,263 on our consolidated balance sheet.
Business Combinations and Contingent Consideration. Acquired businesses are accounted for using the acquisition method of accounting, which requires that the purchase price be allocated to the net assets acquired at their respective fair values. Any excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill. Amounts allocated to contingent consideration are recorded to the balance sheet at the date of acquisition based on their relative fair values. The purchase price allocation requires us to make significant estimates and assumptions, especially at the acquisition date, with respect to intangible assets. Although we believe the assumptions and estimates we have made are reasonable, they are based in part on historical experience and information obtained from the management of the acquired companies and are inherently uncertain.
We account for contingent consideration in accordance with applicable guidance provided within the business combination accounting standard. As part of our consideration for the CoreBiome and Novosanis acquisitions, we are contractually obligated to pay certain consideration resulting from the outcome of future events. Therefore, we are required to update our underlying assumptions each reporting period, based on new developments, and record such contingent consideration liabilities at fair value until the contingency is resolved. Changes in the fair value of the contingent consideration liabilities are recognized each reporting period and included in our consolidated statements of operations. Our estimates
-9-
of fair value are based on assumptions we believe to be reasonable, but the assumptions are uncertain and involve significant judgment by management. Updates to these assumptions could have a significant impact on our results of operations in any given period and any updates to the fair value of the contingent consideration could differ materially from the previous estimates.
Examples of critical estimates used in valuing certain intangible assets and contingent consideration include:
|
|
|
|
|
•
|
|
future expected cash flows from sales and acquired developed technologies;
|
|
|
|
|
|
•
|
|
the acquired company's trade name and customer relationships as well as assumptions about the period of time the acquired trade name and customer relationships will continue to be used in the combined company's portfolio;
|
|
|
|
|
|
•
|
|
the probability of meeting the future events; and
|
|
|
|
|
|
•
|
|
discount rates used to determine the present value of estimated future cash flows.
|
Loss Per Share. Basic and diluted loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted loss per share is generally computed assuming the exercise or vesting of all dilutive securities such as common stock options, unvested performance stock units, and unvested restricted stock. Basic and dilutive computations of net loss per share are the same in periods in which a net loss exists as the dilutive effects of excluded items would be anti-dilutive.
For the three months ended March 31, 2020 and 2019, outstanding common stock options, unvested restricted stock, and unvested performance stock units representing 312 and 779 shares, respectively, were excluded from the computation of diluted earnings per share as their inclusion would have been anti-dilutive.
Foreign Currency Translation. The assets and liabilities of our foreign operations are translated into U.S. dollars at current exchange rates as of the balance sheet date, and revenues and expenses are translated at average exchange rates for the period. Resulting translation adjustments are reflected in accumulated other comprehensive loss, which is a separate component of stockholders’ equity.
Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than a functional currency are included in our consolidated statements of operations in the period in which the change occurs. Net foreign exchange gains (losses) resulting from foreign currency transactions that are included in other income in our consolidated statements of income were $693 and $(609) for the three months ended March 31, 2020 and 2019, respectively.
Accumulated Other Comprehensive Income (Loss). We classify items of other comprehensive income (loss) by their nature and disclose the accumulated balance of other comprehensive loss separately from accumulated deficit and additional paid-in capital in the stockholders’ equity section of our consolidated balance sheets.
We have defined the Canadian dollar as the functional currency of our Canadian subsidiary, DNAG, and we have defined the Euro as the functional currency of our Belgian subsidiary, Novosanis. The results of operations for those subsidiaries are translated into U.S. dollars, which is the reporting currency of the Company. Accumulated other comprehensive loss at March 31, 2020 consists of $21,243 of currency translation adjustments and $556 of net unrealized losses on marketable securities, which represents the fair market value adjustment for our investment portfolio. Accumulated other comprehensive loss at December 31, 2019 consists of $12,022 of currency translation adjustments and $114 of net unrealized losses on marketable securities.
Recent Accounting Pronouncements. In June 2016, the FASB issued guidance on the measurement of credit losses, which requires measurement and recognition of expected credit losses for financial assets, including trade receivables and capital lease receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The method to determine a loss is different from the existing guidance, which requires a credit loss to be recognized when it is probable. We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements as credit losses are not expected to be significant based on historical collection trends, the financial condition of payment partners, and external market factors. The Company will continue to actively monitor the impact of the recent coronavirus (COVID-19) pandemic on expected credit losses. In addition, the new guidance requires us to record an allowance for credit loss when a decline in investment market value is due to credit-related factors. As of January 1, 2020, there was no material decline in the market value of available-for-sale investments due to credit-related factors.
In February 2018, the FASB issued guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the U.S. Tax Cuts and Jobs Act. The guidance is effective in fiscal year 2020, with early adoption permitted, including adoption in an interim period. If elected, the reclassification can be applied in either the period of adoption or retrospectively to the period of the enactment of the U.S. Tax Cuts and Jobs Act (i.e., our first quarter of fiscal year 2018). We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements.
-10-
In August 2018, the FASB issued guidance related to fair value measurement disclosures. This guidance removes the requirement to disclose the amount of and reasons for transfers between Levels 1 and 2 of the fair value hierarchy, the policy for determining that a transfer has occurred, and valuation processes for Level 3 fair value measurements. Additionally, this guidance modifies the disclosures related to the measurement uncertainty for recurring Level 3 fair value measurements (by removing the requirement to disclose sensitivity to future changes) and the timing of liquidation of investee assets (by removing the timing requirement in certain instances). The guidance also requires new disclosures for Level 3 financial assets and liabilities, including the amount and location of unrealized gains and losses recognized in other comprehensive income(loss) and additional information related to significant unobservable inputs used in determining Level 3 fair value measurements. This guidance is effective beginning in fiscal year 2020. We adopted this guidance in the first quarter of 2020 and the impact of the adoption was not material to the Company's consolidated financial statements.
3. Business Combinations
CoreBiome and Novosanis
On January 4, 2019, the Company acquired all of the outstanding stock of CoreBiome, pursuant to the terms of a merger agreement, dated January 3, 2019. Also on January 4, 2019, the Company, through a wholly-owned subsidiary, acquired all of the outstanding stock of Novosanis, pursuant to a share purchase agreement, dated January 3, 2019. We began operating these entities as of the January 4, 2019 closing date. The aggregate purchase price for both of these transactions was $13,320 adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into escrow accounts for a limited period after closing, in order to secure the potential payment of certain indemnification obligations of the selling stockholders under each agreement noted above.
During the three months ended March 31, 2019, we incurred a total of $597 of acquisition-related costs in connection with these acquisitions, including success-based investment banking fees and accounting, legal and other professional fees, related to both acquisitions, all of which were expensed and reported as a component of general and administrative expenses in the consolidated statement of operations for the three months ended March 31, 2019.
Pursuant to our acquisition agreements, we were to pay up to an additional $32,400 of contingent consideration over the next three years based on the achievement of certain performance criteria as defined under the agreements, including generating certain revenue dollars, the achievement of a large customer contract, and the development of certain new technology. The Company, with the assistance of an independent valuation specialist, utilized a Monte Carlo simulation to determine the estimated acquisition-date fair value of the acquisition-related contingent consideration of $4,350. The simulation calculated the probability-weighted payments based on our assessment of the likelihood that the benchmarks will be achieved. The probability-weighted payments were then discounted using a discount rate based on an internal rate of return analysis using the probability-weighted cash flows. The fair value measurement was based on significant inputs, including revenue forecasts, not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration obligation changed from $4,350 as of the acquisition date to $5,625 as of March 31, 2019 as a result of changes in our estimated revenue forecasts. The fair value of the contingent consideration obligation changed from $3,612 as of December 31, 2019 to $1,220 as of March 31, 2020. This change is a result of a $3,500 payment made in the first quarter of 2020, changes in our estimated revenue forecasts and an amendment to one of the agreements. The amendment was entered into in March 2020, in which the terms of the contingent consideration provisions associated with one of the acquisitions were modified and are expected to be paid during the first quarter of 2021. As of March 31, 2020, we may pay up to an additional $22,500 of contingent consideration over the next year and a half.
-11-
The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:
Assets Acquired
|
|
|
|
|
Accounts receivable
|
|
$
|
791
|
|
Inventories
|
|
|
310
|
|
Other current assets
|
|
|
82
|
|
Property, plant, and equipment, net
|
|
|
414
|
|
Other assets
|
|
|
5
|
|
Acquired intangible assets
|
|
|
8,400
|
|
Goodwill
|
|
|
10,368
|
|
Total assets acquired
|
|
|
20,370
|
|
Liabilities Assumed
|
|
|
|
|
Current liabilities
|
|
|
1,180
|
|
Notes payable, short-term
|
|
|
730
|
|
Deferred tax liability
|
|
|
819
|
|
Other long-term liabilities
|
|
|
74
|
|
Total liabilities assumed
|
|
|
2,803
|
|
Net Assets Acquired
|
|
|
17,567
|
|
Estimated fair value of contingent consideration
|
|
|
(4,350
|
)
|
Net Cash Paid (net of cash acquired of $103)
|
|
$
|
13,217
|
|
The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets principally included developed technology, customer relationships, and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:
|
|
Estimated Useful
|
|
|
|
|
Description
|
|
Life (in yrs)
|
|
Amount
|
|
Developed Technology
|
|
10
|
|
$
|
5,000
|
|
Customer relationships
|
|
10
|
|
|
2,200
|
|
Tradenames
|
|
8.34
|
|
|
1,200
|
|
Total acquired intangibles
|
|
|
|
$
|
8,400
|
|
The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of CoreBiome and Novosanis. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.
The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes.
Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our DNAG segment.
Revenues from CoreBiome primarily consist of microbiome laboratory services that utilize optimal analytical algorithms to deliver speed and scalability in the lab with precise analytics. Revenues from Novosanis primarily consist of the sale of its Colli-Pee collection device which was designed for the standard collection of first-void urine used in the liquid biopsy and sexually transmitted infection screening market. Effective as of January 4, 2019, the financial results of CoreBiome and Novosanis are included in our DNAG segment.
Diversigen
On November 8, 2019, the Company acquired all of the outstanding stock of Diversigen pursuant to the terms of a merger agreement. We began operating this entity as of the November 8, 2019 closing date.
-12-
The aggregate purchase price for this transaction was $12,000, adjusted for certain transaction costs, indebtedness, and holdback amounts, and was funded with cash on hand. A portion of the purchase price was deposited into an escrow account for a limited period after closing, pursuant to indemnification obligations under the merger agreement noted above.
During the three months ended March 31, 2020 and 2019, we did not incur any acquisition related costs associated with this transaction, including investment banking fees and accounting, legal and other professional fees.
Pursuant to our acquisition agreements, we were to pay up to an additional $1,500 of contingent consideration in 2020 based on the achievement of certain 2019 revenue metrics as defined under the agreements which did not occur.
The following table summarizes the preliminary estimated fair values of the assets acquired and liabilities assumed as of the acquisition date:
Assets Acquired
|
|
|
|
|
Accounts receivable
|
|
$
|
1,234
|
|
Other current assets
|
|
|
45
|
|
Property, plant, and equipment, net
|
|
|
1,916
|
|
Acquired intangible assets
|
|
|
3,560
|
|
Goodwill
|
|
|
6,317
|
|
Total assets acquired
|
|
|
13,072
|
|
Liabilities Assumed
|
|
|
|
|
Current liabilities
|
|
|
1,123
|
|
Deferred tax liability
|
|
|
598
|
|
Other long-term liabilities
|
|
|
893
|
|
Total liabilities assumed
|
|
|
2,614
|
|
Net Cash Paid (net of cash acquired of $479)
|
|
$
|
10,458
|
|
The purchase price was allocated to the tangible assets and identifiable intangible assets acquired and liabilities assumed based on their acquisition-date estimate fair values. The identifiable intangible assets included customer relationships and tradenames, all of which are subject to amortization on a straight-line basis and are being amortized over estimated useful lives as summarized below:
|
|
Estimated Useful
|
|
|
|
|
Description
|
|
Life (in yrs)
|
|
Amount
|
|
Customer relationships
|
|
10
|
|
|
2,900
|
|
Tradenames
|
|
9
|
|
|
660
|
|
Total acquired intangibles
|
|
|
|
$
|
3,560
|
|
The Company, with the assistance of an independent valuation specialist, assessed the fair value of the assets of Diversigen. The income approach was used to value the acquired intangibles and the fair value measurements were primarily based on significant inputs that are not observable in the market and are considered Level 3 fair value measurements. The income approach estimates fair value for an asset based on the present value of cash flows projected to be generated by the asset. Projected cash flows are discounted at a required rate of return that reflects the relative risk of achieving the cash flows and the time value of money.
The useful lives of the intangible assets were estimated based on the expected future economic benefit of the assets and are being amortized over the estimated useful life in proportion to the economic benefits consumed using the straight-line method. The amortization of intangible assets is not deductible for income tax purposes.
Goodwill is calculated as the difference between the acquisition date fair value of the consideration transferred and the fair value of the net assets acquired, and represents the future economic benefits that we expect to achieve as a result of the acquisition. We believe the goodwill related to the acquisitions was a result of providing us a complementary service and product offering that will enable us to leverage those services and products with existing and new customers. The goodwill is not deductible for income tax purposes. All of the goodwill identified above has been allocated to our DNAG segment.
We continue to evaluate the fair value of certain assets acquired and liabilities assumed. Additional information, which existed as of the acquisition date, but was at that time unknown to us, may become known during the remainder of the measurement period. Changes to amounts recorded as a result of the final determination may result in a corresponding adjustment to these assets and liabilities, including goodwill. The determination of the estimated fair values of all assets acquired is expected to be completed within one year from the date of acquisition.
Revenues from Diversigen primarily consist of microbiome laboratory services that provide metagenomics sequencing, bioinformatics and statistical analysis for the study of the microbiome. Effective as of November 8, 2019, the financial results of Diversigen are included in our DNAG segment.
-13-
Unaudited Pro Forma Financial Information
The unaudited pro forma results presented below include the results of the CoreBiome, Diversigen and Novosanis acquisitions as if they had been consummated as of January 1, 2019. The unaudited pro forma results include the amortization associated with acquired intangible assets and the estimated tax effect of adjustments to income before income taxes but do not include changes in the fair value of our contingent consideration obligations. Material nonrecurring charges, directly attributable to the transactions, including direct acquisition costs, are also excluded. In addition, the unaudited pro forma results do not include any expected benefits of the acquisitions. Accordingly, the unaudited pro forma results are not necessarily indicative of either future results of operations or results that might have been achieved had the acquisitions been consummated as of January 1, 2019.
|
|
Three Months ended
|
|
|
|
March 31, 2019
|
|
|
|
|
|
|
Revenue
|
|
$
|
31,048
|
|
Net loss
|
|
|
(3,290
|
)
|
Net loss per share, basic and diluted
|
|
|
(0.05
|
)
|
Revenues by product. The following table represents total net revenues by product line:
|
|
Three Months Ended March 31,
|
|
|
2020
|
|
|
2019
|
|
|
OraQuick®
|
|
$
|
13,756
|
|
|
$
|
11,590
|
|
|
Oragene®
|
|
|
9,633
|
|
|
|
4,173
|
|
|
ORAcollect®
|
|
|
449
|
|
|
|
3,225
|
|
|
Intercept®
|
|
|
1,978
|
|
|
|
1,842
|
|
|
Microbiome laboratory services
|
|
|
2,447
|
|
|
|
958
|
|
|
OMNIgene® • GUT
|
|
|
693
|
|
|
|
979
|
|
|
Histofreezer® (1)
|
|
|
-
|
|
|
|
2,213
|
|
|
Other products
|
|
|
1,930
|
|
|
|
3,352
|
|
|
Net product and services revenues
|
|
|
30,886
|
|
|
|
28,332
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalty income
|
|
|
446
|
|
|
|
1,084
|
|
|
Other non product revenues
|
|
|
264
|
|
|
|
706
|
|
|
Other revenues
|
|
|
710
|
|
|
|
1,790
|
|
|
Net revenues
|
|
$
|
31,596
|
|
|
$
|
30,122
|
|
|
|
(1)
|
On August 16, 2019, we sold all rights and title to the assets necessary to operate our cryosurgical line of business and as such results of operations after August 16, 2019, do not include any revenues associated with that line of business.
|
Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:
|
|
|
Three Months Ended March 31,
|
|
|
|
|
2020
|
|
|
2019
|
|
United States
|
|
|
$
|
21,616
|
|
|
$
|
20,566
|
|
Europe
|
|
|
|
2,805
|
|
|
|
2,431
|
|
Other regions
|
|
|
|
7,175
|
|
|
|
7,125
|
|
|
|
|
$
|
31,596
|
|
|
$
|
30,122
|
|
Customer and Vendor Concentrations. One of our customers accounted for 12% of our accounts receivable as of March 31, 2020. Another customer accounted for 19% of our accounts receivable as of December 31, 2019. We had no significant customer concentrations (greater than 10%) in our net consolidated revenues for the three months ended March 31, 2020 and 2019
We currently purchase certain products and critical components of our products from sole-supply vendors. If these vendors are unable or unwilling to supply the required components and products, we could be subject to increased costs and substantial delays in the delivery of our products to our customers. Also, our subsidiary, DNAG, uses two third-party suppliers to manufacture its product. Our inability to have a timely supply of any of these components and products could have a material adverse effect on our business, as well as our financial condition and results of operations.
-14-
Deferred Revenue. We record deferred revenue when funds are received prior to the recognition of the associated revenue. Deferred revenue as of March 31, 2020 and December 31, 2019 includes customer prepayments of $2,508 and $1,904, respectively. Deferred revenue as of March 31, 2020 and December 31, 2019 also includes $ 1,804 and $1,809, respectively, associated with a long-term contract that has variable pricing based on volume. The average price over the life of the contract was determined and revenue is recognized at that rate.
5.
|
Accrued Expenses and other current liabilities
|
|
|
March 31, 2020
|
|
|
December 31, 2019
|
|
Payroll and related benefits
|
|
$
|
5,414
|
|
|
$
|
6,088
|
|
Professional fees
|
|
|
2,364
|
|
|
|
2,769
|
|
Other
|
|
|
4,561
|
|
|
|
5,431
|
|
|
|
$
|
12,339
|
|
|
$
|
14,288
|
|
We determine whether an arrangement is a lease at inception. We have operating and finance leases for corporate offices, warehouse space and equipment (including vehicles). As of March 31, 2020, we are the lessee in all agreements. Our leases have remaining lease terms of 1 to 7 years, some of which include options to extend the leases based on agreed upon terms, and some of which include options to terminate the leases within 1 year.
As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments.
We have lease agreements that contain both lease and non-lease components (e.g., common-area maintenance). For these agreements, we account for lease components separate from non-lease components.
The components of lease expense are as follows:
|
|
Three Months Ended March 31,
|
|
|
|
2020
|
|
|
2019
|
|
Operating Lease Cost
|
|
$
|
313
|
|
|
$
|
231
|
|
Finance Lease Cost
|
|
|
|
|
|
|
|
|
Amortization of right-of use assets
|
|
|
163
|
|
|
|
39
|
|
Interest on lease liabilities
|
|
|
20
|
|
|
|
4
|
|
Total Finance Lease Cost
|
|
$
|
183
|
|
|
$
|
43
|
|
|
|
|
|
|
|
|
|
|
Supplemental cash flow information related to leases is as follows:
|
|
Three Months Ended March 31,
|
|
|
|
2020
|
|
|
2019
|
|
Cash paid for amounts included in the measurement of lease liabilities:
|
|
|
|
|
|
|
|
|
Operating cash flows from operating leases
|
|
$
|
316
|
|
|
$
|
228
|
|
Operating cash flows from financing leases
|
|
|
20
|
|
|
|
3
|
|
Financing cash flows from financing leases
|
|
|
175
|
|
|
|
35
|
|
Non-cash activity
|
|
|
|
|
|
|
|
|
Right-of-use assets obtained in exchange for operating lease obligations
|
|
|
—
|
|
|
|
240
|
|
Right-of-use assets obtained in exchange for finance lease obligations
|
|
|
—
|
|
|
|
1,249
|
|
-15-
Supplemental balance sheet information related to leases is as follows:
|
|
March 31, 2020
|
|
|
December 31, 2019
|
|
Operating Leases
|
|
|
|
|
|
|
|
|
Right-of-use assets
|
|
$
|
4,665
|
|
|
$
|
4,996
|
|
|
|
|
|
|
|
|
|
|
Current lease liabilities
|
|
|
999
|
|
|
|
1,032
|
|
Non-current lease liabilities
|
|
|
3,899
|
|
|
|
4,206
|
|
Total operating lease liabilities
|
|
$
|
4,898
|
|
|
$
|
5,238
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance Leases
|
|
|
|
|
|
|
|
|
Right-of-use assets
|
|
$
|
1,818
|
|
|
$
|
1,951
|
|
|
|
|
|
|
|
|
|
|
Current lease liabilities
|
|
|
588
|
|
|
|
613
|
|
Non-current lease liabilities
|
|
|
1,281
|
|
|
|
1,372
|
|
Total finance lease liabilities
|
|
$
|
1,869
|
|
|
$
|
1,985
|
|
Weighted Average Remaining Lease Term
|
|
|
|
|
Weighted-average remaining lease term—operating leases
|
|
|
5.05
|
|
Weighted-average remaining lease term—finance leases
|
|
|
3.27
|
|
|
|
|
|
|
Weighted Average Discount Rate
|
|
|
|
|
Weighted-average discount rate—operating leases
|
|
|
4.29
|
%
|
Weighted-average discount rate—finance leases
|
|
|
4.32
|
%
|
As of March 31, 2020, minimum lease payments by period are expected to be as follows:
|
|
|
|
|
|
|
|
|
Finance
|
|
|
Operating
|
|
2020 (excluding the three months ended March 31, 2020)
|
$
|
512
|
|
|
$
|
928
|
|
2021
|
|
565
|
|
|
|
1,180
|
|
2022
|
|
565
|
|
|
|
1,161
|
|
2023
|
|
336
|
|
|
|
758
|
|
2024
|
|
24
|
|
|
|
776
|
|
Thereafter
|
|
4
|
|
|
|
760
|
|
Total Minimum Lease Payments
|
|
2,006
|
|
|
|
5,563
|
|
Less: imputed interest
|
|
(137
|
)
|
|
|
(665
|
)
|
Present Value of Lease Liabilities
|
$
|
1,869
|
|
|
$
|
4,898
|
|
-16-
Reconciliation of the changes in stockholders' equity for the three months ended March 31, 2020 and 2019
|
|
|
|
Common Stock
|
|
|
Additional
Paid-in
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Loss
|
|
|
Deficit
|
|
|
Total
|
|
Balance at December 31, 2019
|
|
|
61,731
|
|
|
$
|
—
|
|
|
$
|
401,814
|
|
|
$
|
(12,136
|
)
|
|
$
|
(82,533
|
)
|
|
$
|
307,145
|
|
Common stock issued upon exercise
of options
|
|
|
6
|
|
|
|
—
|
|
|
|
30
|
|
|
|
—
|
|
|
|
—
|
|
|
|
30
|
|
Vesting of restricted stock and performance stock units
|
|
|
486
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Purchase and retirement of common shares
|
|
|
(197
|
)
|
|
|
—
|
|
|
|
(1,408
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
(1,408
|
)
|
Stock-based compensation
|
|
|
—
|
|
|
|
—
|
|
|
|
1,376
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1,376
|
|
Net loss
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(7,328
|
)
|
|
|
(7,328
|
)
|
Currency translation adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(9,221
|
)
|
|
|
|
|
|
|
(9,221
|
)
|
Unrealized loss on marketable securities
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(442
|
)
|
|
|
—
|
|
|
|
(442
|
)
|
Balance at March 31, 2020
|
|
|
62,026
|
|
|
$
|
—
|
|
|
$
|
401,812
|
|
|
$
|
(21,799
|
)
|
|
$
|
(89,861
|
)
|
|
$
|
290,152
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock
|
|
|
Additional
Paid-in
|
|
|
Accumulated
Other
Comprehensive
|
|
|
Accumulated
|
|
|
|
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Loss
|
|
|
Deficit
|
|
|
Total
|
|
Balance at December 31, 2018
|
|
|
61,276
|
|
|
$
|
—
|
|
|
$
|
401,273
|
|
|
$
|
(18,706
|
)
|
|
$
|
(99,189
|
)
|
|
$
|
283,378
|
|
Common stock issued upon exercise
of options
|
|
|
4
|
|
|
|
—
|
|
|
|
22
|
|
|
|
—
|
|
|
|
—
|
|
|
|
22
|
|
Vesting of restricted stock and performance stock units
|
|
|
664
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
Purchase and retirement of common shares
|
|
|
(277
|
)
|
|
|
—
|
|
|
|
(3,595
|
)
|
|
|
—
|
|
|
|
—
|
|
|
|
(3,595
|
)
|
Stock-based compensation
|
|
|
—
|
|
|
|
—
|
|
|
|
1,231
|
|
|
|
—
|
|
|
|
—
|
|
|
|
1,231
|
|
Net loss
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
(3,258
|
)
|
|
|
(3,258
|
)
|
Currency translation adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,232
|
|
|
|
|
|
|
|
2,232
|
|
Unrealized gain on marketable securities
|
|
|
—
|
|
|
|
—
|
|
|
|
—
|
|
|
|
497
|
|
|
|
—
|
|
|
|
497
|
|
Balance at March 31, 2019
|
|
|
61,667
|
|
|
$
|
—
|
|
|
$
|
398,931
|
|
|
$
|
(15,977
|
)
|
|
$
|
(102,447
|
)
|
|
$
|
280,507
|
|
Stock-Based Awards
We grant stock-based awards under the OraSure Technologies, Inc. Stock Award Plan, as amended (the “Stock Plan”). The Stock Plan permits stock-based awards to employees, outside directors and consultants or other third-party advisors. Awards which may be granted under the Stock Plan include qualified incentive stock options, nonqualified stock options, stock appreciation rights, restricted awards, performance awards and other stock-based awards. We account for stock-based compensation to employees and directors using the fair value method. We recognize compensation expense for stock option and restricted stock awards issued to employees and directors on a straight-line basis over the requisite service period of the award. We recognize compensation expense related to performance-based restricted stock units based on assumptions as to what percentage of each performance target will be achieved. We evaluate these target assumptions on a quarterly basis and adjust compensation expense related to these awards, as appropriate. To satisfy the exercise of options, issuance of restricted stock, or redemption of performance-based restricted stock units, we issue new shares rather than shares purchased on the open market.
Total compensation cost related to stock options for the three months ended March 31, 2020 and 2019 was $253 and $324 respectively. Net cash proceeds from the exercise of stock options were $30 and $22 for the three months ended March 31, 2020 and 2019, respectively. As a result of our net operating loss carryforward position, no actual income tax benefit was realized from stock option exercises during these periods.
The following table summarizes the stock option activity for the three months ended March 31, 2020:
|
|
Options
|
|
Outstanding on January 1, 2020
|
|
|
1,193
|
|
Granted
|
|
|
510
|
|
Exercised
|
|
|
(6
|
)
|
Forfeited
|
|
|
(14
|
)
|
Outstanding on March 31, 2020
|
|
|
1,683
|
|
-17-
Compensation cost of $1,079 and $653 related to restricted shares was recognized during the three months ended March 31, 2020 and 2019, respectively. In connection with the vesting of restricted shares during the three months ended March 31, 2020 and 2019, we purchased and immediately retired 197 and 277 shares with aggregate values of $1,408 and $3,595, respectively, in satisfaction of minimum tax withholding obligations.
The following table summarizes time-vested restricted stock award and restricted stock unit activity for the three months ended March 31, 2020:
|
|
Units
|
|
Issued and unvested, January 1, 2020
|
|
|
464
|
|
Granted
|
|
|
480
|
|
Vested
|
|
|
(178
|
)
|
Forfeited
|
|
|
(10
|
)
|
Issued and unvested, March 31, 2020
|
|
|
756
|
|
We grant performance-based restricted stock units (“PSUs”) to certain executives. Vesting of these PSUs is dependent upon achievement of performance-based metrics during a one-year or three-year period from the date of grant. Assuming achievement of each performance-based metric, the executive must also generally remain in our service for three years from the grant date. Performance during the one-year period is based on a one-year earnings per share or income before income taxes target. If the one-year target is achieved, the PSUs will then vest three years from grant date. Performance during the three-year period will be based on achievement of a three-year compound annual growth rate for consolidated product revenues. If the three-year target is achieved, the corresponding PSUs will then vest three years from grant date. PSUs are converted into shares of our common stock once vested.
Compensation cost of $44 and $254 related to PSUs was recognized during the three months ended March 31, 2020 and 2019, respectively.
The following table summarizes the PSU activity for the three months ended March 31, 2020:
|
|
Units
|
|
Issued and unvested, January 1, 2020
|
|
|
525
|
|
Granted
|
|
|
353
|
|
Performance adjustment
|
|
|
103
|
|
Vested
|
|
|
(311
|
)
|
Forfeited
|
|
|
(35
|
)
|
Issued and unvested, March 31, 2020
|
|
|
635
|
|
Stock Repurchase Program
On August 5, 2008, our Board of Directors approved a share repurchase program pursuant to which we are permitted to acquire up to $25,000 of our outstanding common shares. No shares were purchased and retired during the three months ended March 31, 2020 and 2019.
During the three months ended March 31, 2020, we recorded income tax expense of $712 which primarily consists of foreign tax expense. During the three months ended March 31, 2019, we recorded and income tax benefit of $29 which primarily consists of a foreign tax benefit offset by nominal domestic tax expense.
Tax expense reflects taxes due to the taxing authorities and the tax effects of temporary differences between the basis of assets and liabilities recognized for financial reporting and tax purposes, and net operating loss and tax credit carryforwards. The significant components of our total deferred tax liability as of March 31, 2020 and December 31, 2019 relate to the tax effects of the basis difference between the intangible assets acquired in our acquisitions for financial reporting and for tax purposes.
In 2008, we established a full valuation allowance against our U.S. deferred tax asset. Management believes the full valuation allowance is still appropriate at both March 31, 2020 and December 31, 2019 since the facts and circumstances necessitating the allowance have not changed. As a result, no U.S. federal or state deferred income tax expense or benefit was recorded for the three month period ended March 31, 2020.
9.
|
Commitments and Contingencies
|
From time to time, we are involved in certain legal actions arising in the ordinary course of business. In management’s opinion, the outcomes of such actions, either individually or in the aggregate, are not expected to have a material adverse effect on our future financial position or results of operations.
-18-
10.
|
Business Segment Information
|
Our business consists of two segments: our “OSUR” business consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using our proprietary technologies, other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. Our DNAG business consists of the development, manufacture, marketing and sale of specimen collection kits that are used to collect, stabilize, transport and store samples of genetic material for molecular testing. Our collection kits are also used for the collection of first-void urine for liquid biopsy in the prostate and bladder cancer markets; and in the sexually transmitted infection screening market. In addition, our DNAG business provides microbiome laboratory services that accelerate research and discovery for customers in the pharmaceutical, agricultural, and academic research markets. Financial results of CoreBiome, Novosanis and Diversigen are included in our DNAG segment. Our cryosurgical systems business was included in our OSUR segment and the impact of the sale of that business in August 2019 is reflected in the results presented below.
We organized our operating segments according to the nature of the products included in those segments. The accounting policies of the segments are the same as those described in the summary of significant accounting policies (see Note 2). We evaluate performance of our operating segments based on revenue and operating income. We do not allocate interest income, interest expense, other income, other expenses or income taxes to our operating segments. Reportable segments have no inter-segment revenues and inter-segment expenses have been eliminated.
The following table summarizes operating segment information for the three months ended March 31, 2020 and 2019, and asset information as of March 31, 2020 and December 31, 2019:
|
|
Three Months Ended March 31,
|
|
|
|
2020
|
|
|
2019
|
|
Net revenues:
|
|
|
|
|
|
|
|
|
OSUR
|
|
$
|
17,792
|
|
|
$
|
18,233
|
|
DNAG
|
|
|
13,804
|
|
|
|
11,889
|
|
Total
|
|
$
|
31,596
|
|
|
$
|
30,122
|
|
Operating loss:
|
|
|
|
|
|
|
|
|
OSUR
|
|
$
|
(7,641
|
)
|
|
$
|
(3,499
|
)
|
DNAG
|
|
|
(405
|
)
|
|
|
(312
|
)
|
Total
|
|
$
|
(8,046
|
)
|
|
$
|
(3,811
|
)
|
Depreciation and amortization:
|
|
|
|
|
|
|
|
|
OSUR
|
|
$
|
861
|
|
|
$
|
822
|
|
DNAG
|
|
|
1,336
|
|
|
|
904
|
|
Total
|
|
$
|
2,197
|
|
|
$
|
1,726
|
|
Capital expenditures:
|
|
|
|
|
|
|
|
|
OSUR
|
|
$
|
818
|
|
|
$
|
1,929
|
|
DNAG
|
|
|
1,777
|
|
|
|
699
|
|
Total
|
|
$
|
2,595
|
|
|
$
|
2,628
|
|
|
|
March 31, 2020
|
|
|
December 31, 2019
|
|
Total assets:
|
|
|
|
|
|
|
|
|
OSUR
|
|
$
|
174,197
|
|
|
$
|
163,943
|
|
DNAG
|
|
|
150,875
|
|
|
|
185,352
|
|
Total
|
|
$
|
325,072
|
|
|
$
|
349,295
|
|
-19-